Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,059 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A desensitization protocol for the mAb cetuximab.
Jerath MR, Kwan M, Kannarkat M, Mirakhur B, Carey L, Valgus J, Platts-Mills TA, Tarrant TK. Jerath MR, et al. Among authors: carey l. J Allergy Clin Immunol. 2009 Jan;123(1):260-2. doi: 10.1016/j.jaci.2008.09.046. Epub 2008 Nov 20. J Allergy Clin Immunol. 2009. PMID: 19022494 No abstract available.
TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer.
Carey LA, Rugo HS, Marcom PK, Mayer EL, Esteva FJ, Ma CX, Liu MC, Storniolo AM, Rimawi MF, Forero-Torres A, Wolff AC, Hobday TJ, Ivanova A, Chiu WK, Ferraro M, Burrows E, Bernard PS, Hoadley KA, Perou CM, Winer EP. Carey LA, et al. J Clin Oncol. 2012 Jul 20;30(21):2615-23. doi: 10.1200/JCO.2010.34.5579. Epub 2012 Jun 4. J Clin Oncol. 2012. PMID: 22665533 Free PMC article. Clinical Trial.
Triple-negative breast cancer: risk factors to potential targets.
Schneider BP, Winer EP, Foulkes WD, Garber J, Perou CM, Richardson A, Sledge GW, Carey LA. Schneider BP, et al. Clin Cancer Res. 2008 Dec 15;14(24):8010-8. doi: 10.1158/1078-0432.CCR-08-1208. Clin Cancer Res. 2008. PMID: 19088017 Review.
TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases.
Anders C, Deal AM, Abramson V, Liu MC, Storniolo AM, Carpenter JT, Puhalla S, Nanda R, Melhem-Bertrandt A, Lin NU, Kelly Marcom P, Van Poznak C, Stearns V, Melisko M, Smith JK, Karginova O, Parker J, Berg J, Winer EP, Peterman A, Prat A, Perou CM, Wolff AC, Carey LA. Anders C, et al. Breast Cancer Res Treat. 2014 Aug;146(3):557-66. doi: 10.1007/s10549-014-3039-y. Epub 2014 Jul 8. Breast Cancer Res Treat. 2014. PMID: 25001612 Free PMC article. Clinical Trial.
Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance).
Sikov WM, Berry DA, Perou CM, Singh B, Cirrincione CT, Tolaney SM, Kuzma CS, Pluard TJ, Somlo G, Port ER, Golshan M, Bellon JR, Collyar D, Hahn OM, Carey LA, Hudis CA, Winer EP. Sikov WM, et al. J Clin Oncol. 2015 Jan 1;33(1):13-21. doi: 10.1200/JCO.2014.57.0572. Epub 2014 Aug 4. J Clin Oncol. 2015. PMID: 25092775 Free PMC article. Clinical Trial.
Circulating tumor cell analysis in metastatic triple-negative breast cancers.
Magbanua MJ, Carey LA, DeLuca A, Hwang J, Scott JH, Rimawi MF, Mayer EL, Marcom PK, Liu MC, Esteva FJ, Park JW, Rugo HS; Translational Breast Cancer Research Consortium. Magbanua MJ, et al. Among authors: carey la. Clin Cancer Res. 2015 Mar 1;21(5):1098-105. doi: 10.1158/1078-0432.CCR-14-1948. Epub 2014 Dec 18. Clin Cancer Res. 2015. PMID: 25524311
1,059 results